Authors


John M. Burke, MD

Latest:

A Close Look at Hodgkin Lymphoma Treatment: Burke Reviews a Phase 2 Study

John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for the treatment of early-stage and advanced classical Hodgkin lymphoma.


Lindsey S. Treviño, PhD

Latest:

Disparities in Access to CAR T-Cell Therapy for Patients With Cancer

Lindsey S. Treviño, PhD, discusses some of the disparities that currently exist among patients with cancer.


Firas B. Badin, MD

Latest:

Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLC

Firas B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.


Mehrdad Abedi, MD

Latest:

Exploring the Use of Orca-T for Patients With Acute and Chronic GVHD

Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.


Bruno Lemos, PhD

Latest:

World Cancer Day: Next Generation Sequencing at the Forefront of Precision Medicine

Next generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.


Milind Javle, MD

Latest:

Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC

Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.


Eric A. Singer, MD

Latest:

Next Steps for Finding Optimal Role for Adjuvant RCC Therapy

Eric A. Singer, MD, MS, discusses future developments that could improve the utilization of adjuvant therapy for high-risk renal cell carcinoma.


Anjana Patel, BSc

Latest:

Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study

Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.


Salman Fazal, MD

Latest:

Fazal on Modalities to Lower the Risk of Acute and Chronic GVHD

Salman Fazal, MD, discusses acute and chronic graft-versus-host-disease and younger match unrelated donor transplant for patients with cancer.


Hayder Saeed, MD

Latest:

Targeted Therapy With Tafasitamab Proves Effective in DLBCL

Hayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.


Charles Powell, MD, MBA

Latest:

Anti-HER2 Treatments Can Cause Pulmonary Toxicities in HER2+ Breast Cancer

Charles Powell, MD, MBA, discusses the questions surrounding pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer.


Cary Gross, MD

Latest:

Link Between Medicaid and Rates of Biomarker Testing in NSCLC

Cary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.


Marco J. de Lima, MD

Latest:

CAR T-Cell Therapy Access Remains Elusive, But Solutions May Be Closer Than Expected

Widespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.


Mary F. Mulcahy, MD

Latest:

Implications of the EPOCH Trial in Clinical Practice

Mary F. Mulcahy discusses the potential implications of the EPOCH trial in clinical practice.


Ryan Sugarman, MD

Latest:

Takeaways From CheckMate-649 in Gastric/GEJ/Esophageal Cancers

Ryan Sugarman, MD, discusses the key takeaways from the CheckMate-649 trial of patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receiving nivolumab combined with chemotherapy compared with chemotherapy alone in the first-line.


Raajit Rampal, MD, PhD

Latest:

Individualized Approaches and Challenges in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.


Wendy Stock, MD

Latest:

Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?

Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.


Riad Salem, MD, MBA

Latest:

Case 4: Later Lines of Therapy for Patients With Recurrent HCC

Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.


David Barrington, MD

Latest:

Future Directions for Treating Stage 1B, Grade 3 Endometrial Cancer

David Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.


Ketan K. Badani, MD

Latest:

Exploring Therapies in Combination With Cytoreductive Nephrectomy in RCC

Ketan K. Badani, MD, discusses whether cytoreductive nephrectomies are efficacious when combined with immunotherapeutic agents in patients with renal cell carcinoma.


Yanghee Woo, MD

Latest:

Debate Assesses FLOT vs CROSS in GEJ Adenocarcinoma

Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.


Nizar Bahlis, MD

Latest:

Updated MAIA Trial Data Show Improved Survival for Multiple Myeloma

Nizar Bahlis, MD, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.


Allison Rosenzweig, PhD

Latest:

World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and Treatment

Lynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.


Connie L. Batlevi, MD, PhD

Latest:

Tazemetostat Shows Benefit in EZH2-Mutated Follicular Lymphoma

Connie L. Batlevi, MD, PhD, discusses the efficacy of tazemetostat in patients with follicular lymphoma and an EZH2 mutation.


Patrick Wagner, MD, FACS

Latest:

Pegsitacianine Informs Surgery in Peritoneal Carcinomatosis

Currently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.


Jonathan L. Kaufman, MD

Latest:

Where Does Inhibition of BCL-2 Family Proteins Fit into the Multiple Myeloma Treatment Landscape?

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.


Johannes Schetelig, MD

Latest:

New Research Challenges ASCT Sequencing in Refractory AML

Johannes Schetelig, MD, MSc, discusses the sequencing of allogeneic stem cell transplant to achieve the best response in patients with acute myeloid leukemia/


Matthew T. Campbell, MD, MS

Latest:

Survival Outcomes for Metastatic RCC and Sarcomatoid Dedifferentiation

Matthew T. Campbell, MD, discusses survival outcomes for patients with both metastatic renal cell carcinoma and sarcomatoid dedifferentiation and how they each have evolved over the past few years.


Naomi G. Dempsey, MD

Latest:

Assessing the Benefits of Endocrine Therapy in Breast Cancer

Naomi Dempsey, MD, discusses her poster presented at the 2023 San Antonio Breast Cancer Symposium analyzing the correlation of the Breast Cancer Index and patient risk factors.


Will Pizii

Latest:

Clinical Activity Is Found With Triplet Combination and ADCs in HER2-Mutant MBC

Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.